about
Lithium for schizophreniaHaloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disordersFlupenthixol versus low-potency first-generation antipsychotic drugs for schizophreniaCarbamazepine for schizophreniaTrifluoperazine versus low-potency first-generation antipsychotic drugs for schizophreniaBenzodiazepines for schizophreniaHaloperidol versus first generation antipsychotics for schizophreniaFlupenthixol versus low-potency first generation antipsychotic drugs for schizophreniaTrifluoperazine versus low-potency first generation antipsychotic drugs for schizophreniaPutting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analysesDiscontinuous patterns of brain activation in the psychotherapy process of obsessive-compulsive disorder: converging results from repeated FMRI and daily self-reports[Neuroimaging the various symptom dimensions of obsessive-compulsive disorder].Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials.Efficacy of pharmacotherapy and psychotherapy for adult psychiatric disorders: a systematic overview of meta-analyses.Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials.Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-analysis and Cochrane review of randomized controlled trials.Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective.The impact of comorbid post-traumatic stress disorder in patients with major depressive disorder on clinical features, pharmacological treatment strategies, and treatment outcomes - Results from a cross-sectional European multicenter study.Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis.Evidence-based pharmacotherapy of treatment-resistant unipolar depression.Increasing placebo response in antipsychotic trials: a clinical perspective.Dose escalation of antipsychotic drugs in schizophrenia: a meta-analysis of randomized controlled trials.Factors contributing to the increasing placebo response in antidepressant trials.PS87. An update on prediction of treatment outcome in treatment resistant depression.Refining Prediction in Treatment-Resistant Depression: Results of Machine Learning Analyses in the TRD III Sample.PS75. Psychopharmacoepidemiology of Major Depressive Disorder in European Tertiary Psychiatric Treatment Centers.PS226. The efficacy of light therapy in the treatment of seasonal affective disorder: A meta-analysis of randomized controlled trials.Early improvement and response to antidepressant medications in adults with major depressive disorder. Meta-analysis and study of a sample with treatment-resistant depression.Pharmacological treatment strategies in unipolar depression in European tertiary psychiatric treatment centers - A pharmacoepidemiological cross-sectional multicenter study.Low comorbid obsessive-compulsive disorder in patients with major depressive disorder - Findings from a European multicenter study.Dose Escalation of Antidepressants in Unipolar Depression: A Meta-Analysis of Double-Blind, Randomized Controlled Trials.Are all first-generation antipsychotics equally effective in treating schizophrenia? A meta-analysis of randomised, haloperidol-controlled trials.Comorbid thyroid disease in patients with major depressive disorder - results from the European Group for the Study of Resistant Depression (GSRD).Clinical correlates of augmentation/combination treatment strategies in major depressive disorder.Major Depression and the Degree of Suicidality: Results of the European Group for the Study of Resistant Depression (GSRD).International Union of Basic and Clinical Pharmacology CIV: The Neurobiology of Treatment-resistant Depression: From Antidepressant Classifications to Novel Pharmacological TargetsClinical factors predicting treatment resistant depression: affirmative results from the European multicenter studySecond-Generation Antipsychotic Drugs in Anorexia Nervosa: A Meta-Analysis of Randomized Controlled TrialsEffektivität einer Augmentationstherapie mit Antipsychotika bei therapieresistenten Zwangsstörungen – eine Metaanalyse doppelblinder, randomisierter, placebokontrollierter StudienClinical factors associated with augmentation treatment with second-generation antipsychotics and lithium in major depression – Results from a European multicenter study
P50
Q24186325-53012EFE-C384-4810-A60D-EB8819D76DB8Q24186601-37F64CC1-6777-439A-8913-D5A180CE5B94Q24193881-E1780354-E770-429C-942B-523233E1C23FQ24194779-7DB3AFF0-F659-4C76-9B83-30E33CD10A41Q24194898-4B43397C-CF14-40D8-898E-02874245011EQ24197501-C1CA9BF7-B6D8-431C-B9C1-794CFDB5A04CQ24198264-1836C0DE-89EB-42F9-AFC0-F9022AD20DB6Q24235116-8D0F2ED4-FE91-4F54-8DEB-4B251376E9E7Q24236681-0A5D0FAA-8F29-448A-B647-2E909525E3C4Q26853468-7121FA38-60E1-4819-BFD5-DC9FE8F91985Q30450424-80E4D9E3-EF42-49E5-9964-C70FE42A079DQ33515856-BA21601F-4CA4-438F-A56E-79C2D670956BQ34296626-BCBF4CD2-949F-4585-BE9E-5D06741014BAQ35161991-BF8F9602-C87F-479A-9818-882822231B48Q36077216-B0411564-2F45-46DB-B812-C15FCF2CDCB9Q38100474-5C272D6C-CC89-4F79-B176-6ABE4A76457EQ38203063-385F3BA5-3DAF-464C-ACF9-44411471435CQ38745972-454C23B7-6B50-48C1-BFF1-49E1F11CA5FBQ38912452-6C1FEC8E-7AFD-4077-BCAB-4F2686BDFE54Q39009865-16081DED-D550-4F76-9B8E-C1788774FCE3Q40783366-FB9F273F-7646-4817-9FD2-CD57D97C266CQ40904206-2A2E256D-AE62-485E-91F8-9107D17A5AFDQ41411906-2C711999-F6C8-467C-B3E4-B99E232D50EDQ45918751-ACA34B00-9CEB-4574-911A-48E5D213B38AQ45943071-5ABC85DF-1BF7-41F9-B1EE-58BFA6759FEBQ47120001-02CCBB6F-D07C-47DB-9E77-83BFEAF7BC82Q47140906-4D324310-B298-4252-9992-C25487F18D7CQ47288933-ADC4F142-AEB7-4731-9A67-002C40D69F09Q47637703-0327CF57-6002-4FA5-B7D0-BC7A271E92C1Q47717780-10D51F70-61BA-4185-8561-7F1C2D21C3F9Q47770326-ECEDDE05-AF68-4B12-BFD7-438D4B39D7A5Q50540496-BA766511-80BE-4D21-BD9C-5062C5CF9E8AQ50540496-C929EE46-A839-4F6C-81C4-54FE3AB17448Q53690557-BE476EC1-324B-4AFE-98C9-0A7A8E276C69Q55037377-C7C64116-1D80-4353-9E99-19959A804561Q55365950-159C6A7E-A28B-4C28-BE5A-D519F024D567Q56377231-BF777B5A-EDC1-4748-82F4-35B051304365Q57020822-DA424A99-3C68-458D-9EF5-DD624D7C0EABQ57737987-E5595F5E-A78E-429C-B636-EEE32B10A2DBQ57738294-386D8198-7315-46BB-B126-8F91986FB84F
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Markus Dold
@ast
Markus Dold
@en
Markus Dold
@es
Markus Dold
@sl
type
label
Markus Dold
@ast
Markus Dold
@en
Markus Dold
@es
Markus Dold
@sl
prefLabel
Markus Dold
@ast
Markus Dold
@en
Markus Dold
@es
Markus Dold
@sl
P106
P21
P31
P496
0000-0001-8914-2192